期刊文献+

乳腺癌治疗决策:从个体化治疗到精准医学 被引量:34

Decision making for breast cancer:From the individualized treatment to precision medicine plan
原文传递
导出
摘要 最近召开的第14届St.Gallen国际乳腺癌会议提出"个体化治疗到精准医学"的理念。会议聚焦早期乳腺癌治疗决策的个体化、精准医学和大数据等内容。临床研究优化了治疗方案,推动了治疗指南的制定和修改,带来了新的医学策略的思考。随着近年来个体化诊断及治疗手段的发展,乳腺癌治疗决策已步入了精准医学的新时代。 The 14 th St. Gallen international meeting is theexpert congress to discuss and update the consensus for earlystage breast cancer(St. Gallen consensus),with "individualized medicine to the precision medicine" as thetheme. The concept and topics on individualized treatment forbreast cancer,the precision medicine plan and the utilizationof big data were involved and hotly debated in the conference.The clinical researches play a very important role inoptimization of treatment decision making,developing andmodification of clinical guidelines,initiation of the newmedical strategy thinking. In addition,with the development ofthe individualized diagnosis and treatment method,a new eraof precision medicine has been opened up.
作者 江泽飞
出处 《中国实用外科杂志》 CSCD 北大核心 2015年第7期697-700,共4页 Chinese Journal of Practical Surgery
关键词 乳腺癌 个体化治疗 精准医学 breast cancer individualized treatment precision medicine
  • 相关文献

参考文献11

  • 1Budd GT, Barlow WE, Moore HCF, et al. SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk ear- ly-stage breast cancer[J]. J Clin Oncol, 2015, 33(1): 58-64. 被引量:1
  • 2Samuel JA, Wilson JW, Bandos H. NSABP B-36: a randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adria- mycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer [C]. San Antonio Breast Cancer Symposium, 2014: S3-02. 被引量:1
  • 3Eiermann W, Pienkowski T, Crown J, et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequen- tial docetaxel as adjuvant treatment in patients with human epi- dermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial [J]. J Clin Oncol, 2011, 29(29): 3877-3884. 被引量:1
  • 4Davies C. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a ran- domised trial [J]. Lancet, 2013, 381(9869): 804-804. 被引量:1
  • 5Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA. 17 trial: analyses: adjusting for treatment crossover [J]. J Clin Oncol, 2012, 30(7): 718-721. 被引量:1
  • 6Pagani O, Regan MM, Walley B, et al: Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (3") plus OFS in pre- menopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT tri- als [C].ASCO Annual Meeting Proceedings, 2014, 32(18 suppl): LBA 1. 被引量:1
  • 7Francis PA, Regan MM, Fleming GF. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (0FS) versus tamoxifen in premenopausal women with hormone recep- tor-positive (HR + ) early breast cancer (BC): analysis of the SOFT trial [C~. San Antnni9 Breast Cancer Symposium, 2014: $3-08. 被引量:1
  • 8Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial [J]. Lancet Oncol, 2010, 11 (12): 1135-1141. 被引量:1
  • 9Regan MM, Neven P, Giobbie-Hurder A, et al. BIG 1-98 Col- laborative Group; International Breast Cancer Study Group (IBC- SG). Assessment of letrozole and tamoxifen alone and in se- quence for postmenopausal women with steroid hormone recep- tor-positive breast cancer: the BIG 1-98 randomised clinical tri- al at 8.1 years median follow-up [J]. Lancet Oncol, 2011, 12 (12): 1101-1108. 被引量:1
  • 10Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall surviv- al: fulvestrant 500rag vs 250rag in the randomized CONFIRM trial[J]. J Nati Cancer Inst, 2014,106(1):djt 337. 被引量:1

同被引文献305

引证文献34

二级引证文献267

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部